Supported by an investment between Medtronic, Inc. and DaVita Inc., Mozarc Medical is an independent company that leverages both companies’ leadership and expertise to develop transformative kidney health technologies. Headquartered in Minneapolis, Minnesota, Mozarc Medical’s mission is to reshape all aspects of kidney health with technology that enriches patients’ lives. The company’s product portfolio spans advanced dialysis technologies, access solutions, and support resources for clinicians and caregivers, emphasizing clinical precision, usability, and outcomes.
The Carpediem™ System by Mozarc Medical: A Breakthrough in Neonatal Renal Support
One of Mozarc Medical’s most impactful innovations is the Carpediem™ cardiorenal pediatric dialysis emergency machine, a continuous renal replacement therapy (CRRT) system designed specifically for patients weighing between 2.5-10kg. Traditional dialysis machines designed for adults can be difficult to use safely in tiny patients. Carpediem™ was engineered from the ground up to meet the unique needs of the most fragile patients, without the increased risks and complexities of adult machine adaptation.
What Carpediem™ Does
- Continuous Renal Replacement Therapy (CRRT): Provides life-sustaining dialysis support for acute kidney injury (AKI) and fluid overload in neonates and infants.
- Precision for tiny patients: Built with low priming volume, high-precision fluid scales (±1 g), and support for low blood flow rates; these features help maintain stability in infants weighing as little as 5.5lb (2.5kg).
- Multiple modalities: Supports continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF).
Clinical Studies:
A summary of clinical data is available on Mozarc’s Carpediem web page linked here.
Notably, in results from the clinical study “Survival of infants treated with CKRT: comparing adapted adult platforms with the Carpediem™”, infants treated had a 97% survival rate at the end of treatment with Carpediem ™1
Why the Carpediem™ Matters
Acute kidney injury and fluid overload in neonates are serious conditions that can contribute to high morbidity and mortality, if not managed effectively. Because newborns have very small blood volumes and unique challenges, dialysis systems must be carefully calibrated for their size and fragility. The miniaturized platform 1,2 and precise fluid management tools of Carpediem ™ make it possible to deliver CRRT modalities safely and effectively in these cases, an advancement many clinicians describe as transformative for neonatal kidney care.
Real-World Adoption
Mozarc Medical continues to expand its reach and partnerships, including collaborations with organizations like the Fetal Health Foundation, to raise awareness of neonatal dialysis innovations, and support clinicians and families navigating complex care scenarios. As the company grows, Mozarc Medical is focused on broadening access to its technology by expanding adoption of Carpediem™ beyond its current presence in more than 200 specialized neonatal care centers across the country. The goal is to extend advanced neonatal renal support to a wider range of hospitals and care settings, ensuring more infants can receive timely, specialized treatment closer to home.
Find out more about Mozarc Medical
Learn more about the Carpediem System
References:
- Ronco C, Garzotto F, Ricci Z. CA.R.PE.DI.E.M. (Cardio-Renal Pediatric Dialysis Emergency Machine): evolution of continuous renal replacement therapies in infants. A personal journey. Pediatr Nephrol. 2012;27(8):1203–1211.
- Carpediem™ dialysis system [Operator’s Manual]. Minneapolis, MN: Medtronic; 2022.
